| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 117 | 2024 | 2281 | 19.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 190 | 2024 | 7017 | 14.090 |
Why?
|
| Transplantation, Autologous | 110 | 2024 | 2045 | 10.110 |
Why?
|
| Transplantation Conditioning | 72 | 2024 | 2368 | 5.070 |
Why?
|
| Melphalan | 47 | 2023 | 875 | 4.860 |
Why?
|
| Graft vs Host Disease | 55 | 2024 | 2808 | 3.110 |
Why?
|
| Stem Cell Transplantation | 28 | 2023 | 1414 | 3.110 |
Why?
|
| Amyloidosis | 10 | 2023 | 173 | 3.070 |
Why?
|
| Myeloablative Agonists | 17 | 2022 | 386 | 2.150 |
Why?
|
| Busulfan | 27 | 2024 | 792 | 2.080 |
Why?
|
| Transplantation, Homologous | 54 | 2024 | 3043 | 2.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 62 | 2024 | 16669 | 1.800 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 12 | 2023 | 270 | 1.720 |
Why?
|
| Middle Aged | 183 | 2024 | 90334 | 1.610 |
Why?
|
| Chromosome Aberrations | 15 | 2024 | 2031 | 1.610 |
Why?
|
| Adult | 167 | 2024 | 81975 | 1.590 |
Why?
|
| Aged | 149 | 2024 | 73375 | 1.550 |
Why?
|
| POEMS Syndrome | 4 | 2022 | 22 | 1.550 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 9 | 2018 | 218 | 1.520 |
Why?
|
| Retrospective Studies | 93 | 2024 | 39827 | 1.500 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2016 | 104 | 1.470 |
Why?
|
| Treatment Outcome | 88 | 2024 | 33733 | 1.440 |
Why?
|
| Disease-Free Survival | 50 | 2022 | 10260 | 1.440 |
Why?
|
| Humans | 271 | 2024 | 270744 | 1.440 |
Why?
|
| Autografts | 13 | 2023 | 179 | 1.370 |
Why?
|
| Male | 174 | 2024 | 128374 | 1.310 |
Why?
|
| Female | 175 | 2024 | 148945 | 1.210 |
Why?
|
| Cyclophosphamide | 20 | 2024 | 3243 | 1.200 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 4 | 2023 | 31 | 1.190 |
Why?
|
| Induction Chemotherapy | 5 | 2021 | 670 | 1.160 |
Why?
|
| Antigens, CD34 | 8 | 2024 | 639 | 1.110 |
Why?
|
| Leukemia, Myeloid, Acute | 32 | 2023 | 7263 | 1.100 |
Why?
|
| Hematologic Neoplasms | 18 | 2023 | 1955 | 1.080 |
Why?
|
| Dexamethasone | 14 | 2023 | 1507 | 0.970 |
Why?
|
| Leukemia, Plasma Cell | 3 | 2020 | 42 | 0.930 |
Why?
|
| Cancer Vaccines | 3 | 2022 | 754 | 0.910 |
Why?
|
| Recurrence | 35 | 2024 | 4875 | 0.890 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2018 | 604 | 0.860 |
Why?
|
| Bortezomib | 12 | 2023 | 543 | 0.850 |
Why?
|
| Survival Analysis | 30 | 2022 | 9290 | 0.820 |
Why?
|
| Vidarabine | 19 | 2022 | 1383 | 0.780 |
Why?
|
| Prognosis | 42 | 2024 | 22480 | 0.770 |
Why?
|
| Remission Induction | 22 | 2024 | 3652 | 0.770 |
Why?
|
| Survival Rate | 39 | 2022 | 12526 | 0.760 |
Why?
|
| Hodgkin Disease | 12 | 2022 | 1485 | 0.760 |
Why?
|
| Adoptive Transfer | 2 | 2022 | 431 | 0.710 |
Why?
|
| Kidney Diseases | 2 | 2016 | 693 | 0.710 |
Why?
|
| Deoxycytidine | 9 | 2024 | 1389 | 0.700 |
Why?
|
| Thalidomide | 12 | 2017 | 595 | 0.690 |
Why?
|
| Combined Modality Therapy | 23 | 2021 | 9039 | 0.680 |
Why?
|
| Translocation, Genetic | 4 | 2023 | 1285 | 0.680 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 552 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2023 | 10385 | 0.660 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2024 | 214 | 0.660 |
Why?
|
| Maintenance Chemotherapy | 7 | 2021 | 224 | 0.660 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2016 | 2634 | 0.650 |
Why?
|
| Virus Activation | 2 | 2019 | 236 | 0.630 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2308 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2023 | 1738 | 0.610 |
Why?
|
| Heart Diseases | 3 | 2015 | 723 | 0.600 |
Why?
|
| Myelodysplastic Syndromes | 15 | 2023 | 3152 | 0.600 |
Why?
|
| Vaccination | 2 | 2022 | 1164 | 0.600 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 550 | 0.600 |
Why?
|
| Lymphoma | 10 | 2024 | 1520 | 0.600 |
Why?
|
| Gastrointestinal Diseases | 4 | 2024 | 607 | 0.600 |
Why?
|
| Infection Control | 1 | 2020 | 276 | 0.590 |
Why?
|
| Amifostine | 1 | 2018 | 99 | 0.590 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2023 | 770 | 0.580 |
Why?
|
| Young Adult | 53 | 2024 | 22216 | 0.580 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2017 | 7 | 0.570 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 15210 | 0.570 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 57 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 1052 | 0.560 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2019 | 287 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 10 | 2023 | 1387 | 0.540 |
Why?
|
| Heterocyclic Compounds | 4 | 2023 | 117 | 0.540 |
Why?
|
| Hematology | 1 | 2017 | 99 | 0.530 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2022 | 2902 | 0.530 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2016 | 131 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2019 | 413 | 0.530 |
Why?
|
| HLA-A2 Antigen | 1 | 2016 | 172 | 0.520 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 43 | 0.520 |
Why?
|
| Precision Medicine | 1 | 2023 | 1208 | 0.510 |
Why?
|
| Neoplasm, Residual | 8 | 2023 | 1752 | 0.510 |
Why?
|
| Lymphocyte Transfusion | 4 | 2017 | 174 | 0.500 |
Why?
|
| Drug Administration Schedule | 7 | 2015 | 3530 | 0.480 |
Why?
|
| Neoplasm Staging | 10 | 2024 | 14012 | 0.480 |
Why?
|
| Myeloproliferative Disorders | 4 | 2023 | 882 | 0.480 |
Why?
|
| Tacrolimus | 6 | 2023 | 347 | 0.470 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2017 | 372 | 0.470 |
Why?
|
| Outpatients | 1 | 2017 | 463 | 0.470 |
Why?
|
| Antineoplastic Agents | 17 | 2022 | 14616 | 0.470 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1655 | 0.460 |
Why?
|
| Aged, 80 and over | 25 | 2024 | 31006 | 0.460 |
Why?
|
| Amyloid | 2 | 2014 | 91 | 0.460 |
Why?
|
| Adolescent | 52 | 2024 | 32735 | 0.460 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2017 | 409 | 0.450 |
Why?
|
| Gene Amplification | 1 | 2016 | 766 | 0.440 |
Why?
|
| Social Media | 1 | 2017 | 208 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 329 | 0.430 |
Why?
|
| Histocompatibility Testing | 7 | 2019 | 487 | 0.420 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 114 | 0.410 |
Why?
|
| Inpatients | 1 | 2017 | 686 | 0.400 |
Why?
|
| Respirovirus | 1 | 2011 | 6 | 0.400 |
Why?
|
| Ascorbic Acid | 2 | 2011 | 131 | 0.400 |
Why?
|
| Respirovirus Infections | 1 | 2011 | 30 | 0.390 |
Why?
|
| Salvage Therapy | 8 | 2021 | 2122 | 0.390 |
Why?
|
| Oxides | 2 | 2011 | 212 | 0.390 |
Why?
|
| Incidence | 13 | 2024 | 5825 | 0.390 |
Why?
|
| Agammaglobulinemia | 1 | 2011 | 50 | 0.390 |
Why?
|
| Arsenicals | 2 | 2011 | 205 | 0.390 |
Why?
|
| Boronic Acids | 3 | 2013 | 354 | 0.390 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2011 | 75 | 0.390 |
Why?
|
| Tissue Donors | 5 | 2022 | 815 | 0.380 |
Why?
|
| Plasma Cells | 4 | 2023 | 196 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 500 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 6255 | 0.380 |
Why?
|
| Graft Survival | 12 | 2017 | 1081 | 0.370 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2021 | 284 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2023 | 839 | 0.370 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2024 | 135 | 0.370 |
Why?
|
| Dendritic Cells | 7 | 2023 | 1110 | 0.360 |
Why?
|
| Peptides | 1 | 2016 | 1504 | 0.360 |
Why?
|
| Immunoglobulin D | 1 | 2010 | 17 | 0.360 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2011 | 191 | 0.360 |
Why?
|
| Acute Disease | 13 | 2024 | 2496 | 0.360 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 690 | 0.360 |
Why?
|
| Blood Component Removal | 1 | 2010 | 119 | 0.360 |
Why?
|
| Pyrazines | 3 | 2013 | 510 | 0.350 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2013 | 441 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 5070 | 0.340 |
Why?
|
| Time Factors | 17 | 2021 | 13021 | 0.330 |
Why?
|
| Drug Monitoring | 1 | 2011 | 352 | 0.330 |
Why?
|
| Medical Oncology | 2 | 2017 | 1465 | 0.330 |
Why?
|
| Phenotype | 1 | 2020 | 6516 | 0.320 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 1067 | 0.310 |
Why?
|
| T-Lymphocytes | 7 | 2020 | 3944 | 0.310 |
Why?
|
| Fetal Blood | 3 | 2017 | 501 | 0.300 |
Why?
|
| Immunosuppressive Agents | 7 | 2017 | 1429 | 0.300 |
Why?
|
| Lymphoma, Follicular | 3 | 2021 | 636 | 0.290 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 1049 | 0.290 |
Why?
|
| Adenoviridae | 1 | 2013 | 1497 | 0.290 |
Why?
|
| Antigens, CD19 | 3 | 2024 | 584 | 0.290 |
Why?
|
| Transplantation, Isogeneic | 2 | 2017 | 67 | 0.290 |
Why?
|
| Case-Control Studies | 4 | 2018 | 6237 | 0.290 |
Why?
|
| Unrelated Donors | 4 | 2018 | 321 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 3176 | 0.280 |
Why?
|
| Stroke Volume | 1 | 2009 | 544 | 0.280 |
Why?
|
| Allografts | 9 | 2024 | 686 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 592 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2023 | 1366 | 0.280 |
Why?
|
| Rituximab | 8 | 2023 | 1593 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 3656 | 0.270 |
Why?
|
| Vincristine | 4 | 2022 | 1582 | 0.270 |
Why?
|
| Prospective Studies | 21 | 2024 | 13414 | 0.270 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 310 | 0.270 |
Why?
|
| Strongyloidiasis | 1 | 2006 | 55 | 0.270 |
Why?
|
| Risk Factors | 23 | 2024 | 17896 | 0.260 |
Why?
|
| Graft vs Tumor Effect | 3 | 2017 | 143 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 354 | 0.260 |
Why?
|
| Mycophenolic Acid | 4 | 2022 | 153 | 0.260 |
Why?
|
| Recovery of Function | 1 | 2009 | 684 | 0.260 |
Why?
|
| Age Factors | 8 | 2018 | 5465 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 128 | 0.250 |
Why?
|
| Antioxidants | 1 | 2008 | 522 | 0.250 |
Why?
|
| Retreatment | 3 | 2017 | 447 | 0.250 |
Why?
|
| Bone Marrow | 7 | 2021 | 2438 | 0.250 |
Why?
|
| Photopheresis | 2 | 2021 | 79 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 213 | 0.240 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 4328 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.240 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 99 | 0.230 |
Why?
|
| Lymphocyte Depletion | 2 | 2018 | 316 | 0.230 |
Why?
|
| Leukapheresis | 4 | 2013 | 166 | 0.230 |
Why?
|
| Killer Cells, Natural | 3 | 2024 | 965 | 0.230 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 4889 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 125 | 0.230 |
Why?
|
| Hemocyanins | 2 | 2022 | 54 | 0.230 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 1580 | 0.230 |
Why?
|
| Obesity, Abdominal | 1 | 2024 | 45 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 914 | 0.220 |
Why?
|
| Antilymphocyte Serum | 4 | 2012 | 237 | 0.220 |
Why?
|
| Propensity Score | 3 | 2021 | 771 | 0.220 |
Why?
|
| Anemia, Aplastic | 3 | 2010 | 232 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 6 | 2016 | 4480 | 0.220 |
Why?
|
| Immunophenotyping | 3 | 2016 | 1726 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2013 | 1185 | 0.210 |
Why?
|
| Blood Donors | 3 | 2013 | 173 | 0.210 |
Why?
|
| Refrigeration | 1 | 2022 | 15 | 0.210 |
Why?
|
| Central Nervous System | 2 | 2022 | 453 | 0.200 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 4374 | 0.200 |
Why?
|
| HLA Antigens | 3 | 2014 | 594 | 0.200 |
Why?
|
| Disease Progression | 9 | 2019 | 6855 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2023 | 173 | 0.200 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 5102 | 0.200 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2023 | 120 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 235 | 0.190 |
Why?
|
| Immunologic Factors | 3 | 2023 | 672 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 2 | 2020 | 929 | 0.190 |
Why?
|
| Treatment Failure | 4 | 2021 | 1428 | 0.190 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 1020 | 0.190 |
Why?
|
| Fatal Outcome | 3 | 2010 | 824 | 0.190 |
Why?
|
| Adenine Nucleotides | 4 | 2016 | 365 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Child | 21 | 2024 | 30538 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Arabinonucleosides | 4 | 2016 | 470 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2024 | 1840 | 0.180 |
Why?
|
| Gene Deletion | 2 | 2016 | 1473 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 109 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 2 | 2019 | 495 | 0.170 |
Why?
|
| Oligopeptides | 1 | 2022 | 447 | 0.170 |
Why?
|
| Models, Biological | 2 | 2019 | 3194 | 0.170 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 10706 | 0.170 |
Why?
|
| Carmustine | 4 | 2019 | 224 | 0.160 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.160 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 20 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 1267 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 737 | 0.160 |
Why?
|
| Doxorubicin | 5 | 2022 | 3145 | 0.160 |
Why?
|
| Vomiting | 2 | 2018 | 362 | 0.160 |
Why?
|
| Proteasome Inhibitors | 2 | 2017 | 232 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 3 | 2024 | 1757 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2024 | 6768 | 0.160 |
Why?
|
| Nausea | 2 | 2018 | 540 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 202 | 0.150 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 416 | 0.150 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2017 | 9 | 0.150 |
Why?
|
| Histocompatibility | 3 | 2018 | 183 | 0.150 |
Why?
|
| Transplantation Immunology | 4 | 2019 | 106 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 1544 | 0.150 |
Why?
|
| Pentostatin | 1 | 2017 | 121 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 3845 | 0.150 |
Why?
|
| Biomarkers | 4 | 2016 | 5060 | 0.150 |
Why?
|
| Etoposide | 5 | 2018 | 907 | 0.140 |
Why?
|
| Heart Failure | 1 | 2010 | 2333 | 0.140 |
Why?
|
| Sickness Impact Profile | 1 | 2017 | 138 | 0.140 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.140 |
Why?
|
| Receptors, KIR | 1 | 2017 | 64 | 0.140 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 870 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 728 | 0.140 |
Why?
|
| Feasibility Studies | 5 | 2016 | 2363 | 0.140 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 92 | 0.140 |
Why?
|
| Cohort Studies | 7 | 2020 | 9473 | 0.130 |
Why?
|
| Cause of Death | 2 | 2017 | 788 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 149 | 0.130 |
Why?
|
| Consolidation Chemotherapy | 2 | 2019 | 153 | 0.130 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 27 | 0.130 |
Why?
|
| Hydroxamic Acids | 2 | 2016 | 454 | 0.130 |
Why?
|
| Prednisone | 1 | 2018 | 1033 | 0.130 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 496 | 0.130 |
Why?
|
| Hospitalization | 2 | 2020 | 2168 | 0.130 |
Why?
|
| Filgrastim | 3 | 2010 | 194 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Steroids | 4 | 2021 | 371 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 2196 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2014 | 878 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2016 | 228 | 0.130 |
Why?
|
| Child, Preschool | 11 | 2021 | 17043 | 0.130 |
Why?
|
| Biopsy | 3 | 2020 | 3483 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 250 | 0.120 |
Why?
|
| Liver Diseases | 2 | 2017 | 602 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 1089 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 324 | 0.120 |
Why?
|
| Neutrophils | 3 | 2015 | 873 | 0.120 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2014 | 43 | 0.120 |
Why?
|
| Ring Chromosomes | 1 | 2014 | 17 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2016 | 380 | 0.120 |
Why?
|
| Diarrhea | 1 | 2018 | 716 | 0.120 |
Why?
|
| Whole-Body Irradiation | 3 | 2016 | 323 | 0.110 |
Why?
|
| Probability Theory | 1 | 2013 | 6 | 0.110 |
Why?
|
| Cytogenetic Analysis | 3 | 2020 | 574 | 0.110 |
Why?
|
| Quality of Life | 3 | 2024 | 4775 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 714 | 0.110 |
Why?
|
| Bayes Theorem | 2 | 2021 | 1060 | 0.110 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 2344 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 593 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 234 | 0.110 |
Why?
|
| Blood Platelets | 2 | 2015 | 677 | 0.110 |
Why?
|
| Blood Volume | 1 | 2013 | 107 | 0.110 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2013 | 33 | 0.110 |
Why?
|
| Thiotepa | 3 | 2012 | 132 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2013 | 241 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 304 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2013 | 122 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 366 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2012 | 44 | 0.100 |
Why?
|
| Transcriptome | 1 | 2021 | 1960 | 0.100 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 35 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 864 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 402 | 0.100 |
Why?
|
| Biometry | 1 | 2013 | 250 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2022 | 1825 | 0.090 |
Why?
|
| Transplantation, Haploidentical | 2 | 2022 | 159 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 205 | 0.090 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2010 | 34 | 0.090 |
Why?
|
| Piperazines | 2 | 2010 | 2145 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Immunization | 1 | 2012 | 399 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 813 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 196 | 0.090 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 74 | 0.090 |
Why?
|
| Myeloblastin | 1 | 2010 | 65 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 393 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2014 | 460 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2026 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2010 | 3028 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 381 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 598 | 0.090 |
Why?
|
| Topotecan | 1 | 2010 | 248 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 50 | 0.080 |
Why?
|
| Methotrexate | 2 | 2023 | 1025 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 232 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2010 | 177 | 0.080 |
Why?
|
| United States | 7 | 2023 | 15853 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2651 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 1311 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1442 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2022 | 3045 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4963 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 2392 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 625 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1857 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2014 | 749 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1486 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3346 | 0.080 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 165 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2013 | 1570 | 0.070 |
Why?
|
| Cytarabine | 3 | 2019 | 2013 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 2453 | 0.070 |
Why?
|
| Holmium | 1 | 2007 | 24 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 529 | 0.070 |
Why?
|
| Neoplasms | 2 | 2024 | 15919 | 0.070 |
Why?
|
| Logistic Models | 1 | 2014 | 3448 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2010 | 3667 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2007 | 91 | 0.070 |
Why?
|
| Thiabendazole | 1 | 2006 | 11 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 730 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2007 | 233 | 0.070 |
Why?
|
| Ivermectin | 1 | 2006 | 19 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 4961 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1035 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2007 | 178 | 0.070 |
Why?
|
| Anthelmintics | 1 | 2006 | 72 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 838 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 1251 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2006 | 86 | 0.070 |
Why?
|
| Apoptosis | 1 | 2020 | 7754 | 0.060 |
Why?
|
| Leukemia, Myeloid | 2 | 2007 | 993 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5403 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2010 | 1309 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2012 | 1437 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 2484 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1311 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2024 | 81 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2020 | 12102 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1416 | 0.060 |
Why?
|
| Necrosis | 1 | 2005 | 595 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 348 | 0.060 |
Why?
|
| Transplantation Chimera | 2 | 2014 | 173 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2013 | 233 | 0.050 |
Why?
|
| Polyvinyl Chloride | 1 | 2022 | 9 | 0.050 |
Why?
|
| Drug Packaging | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2010 | 683 | 0.050 |
Why?
|
| beta-Cyclodextrins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2024 | 190 | 0.050 |
Why?
|
| Propylene Glycols | 1 | 2022 | 39 | 0.050 |
Why?
|
| Drug Stability | 1 | 2022 | 106 | 0.050 |
Why?
|
| Drug Storage | 1 | 2022 | 30 | 0.050 |
Why?
|
| North America | 1 | 2023 | 337 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 107 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1135 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3900 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2022 | 159 | 0.050 |
Why?
|
| Boron Compounds | 1 | 2022 | 69 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 2057 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 110 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 761 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 275 | 0.050 |
Why?
|
| Animals | 4 | 2024 | 62045 | 0.050 |
Why?
|
| Benzylamines | 2 | 2013 | 98 | 0.050 |
Why?
|
| Diterpenes | 1 | 2022 | 115 | 0.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 513 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 277 | 0.050 |
Why?
|
| Temperature | 1 | 2022 | 538 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2022 | 590 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 318 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 167 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 179 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1312 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2020 | 65 | 0.040 |
Why?
|
| Glycine | 1 | 2022 | 319 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 206 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 126 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 65 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2011 | 358 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 418 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 416 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2017 | 2588 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 213 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2014 | 735 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 50 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3408 | 0.040 |
Why?
|
| Liver | 2 | 2005 | 3089 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 1723 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 324 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 562 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 2846 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1469 | 0.040 |
Why?
|
| Texas | 3 | 2013 | 6447 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 574 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4829 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 1998 | 267 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1542 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 253 | 0.030 |
Why?
|
| Placebos | 1 | 2017 | 443 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 347 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 336 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2024 | 2238 | 0.030 |
Why?
|
| Cytokines | 2 | 2016 | 2826 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 133 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 3604 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 252 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 286 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2010 | 1691 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 374 | 0.030 |
Why?
|
| Lorazepam | 1 | 1995 | 40 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 610 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 106 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 150 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 166 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 936 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1822 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Benzamides | 2 | 2010 | 1879 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 485 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 97 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 1406 | 0.030 |
Why?
|
| Living Donors | 1 | 2014 | 175 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 657 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Infant | 3 | 2015 | 13985 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2016 | 423 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 347 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2012 | 53 | 0.030 |
Why?
|
| Pedigree | 1 | 1997 | 2042 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 513 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1320 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4497 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2012 | 213 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 1838 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 667 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2184 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 14838 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 149 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 655 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1940 | 0.020 |
Why?
|
| Survivors | 2 | 2007 | 1023 | 0.020 |
Why?
|
| Neutropenia | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 612 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 246 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 184 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 1496 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 311 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2020 | 1933 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 440 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6192 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 432 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 574 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 5002 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 707 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 8124 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 428 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 909 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1359 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5149 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 634 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1714 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 467 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2009 | 107 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3401 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 600 | 0.020 |
Why?
|
| Cisplatin | 1 | 1995 | 2496 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 144 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 35594 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 218 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 120 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 907 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2008 | 310 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 5437 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1825 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 1717 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 342 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1571 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1588 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2006 | 16205 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 1910 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 224 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 1988 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 4943 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2009 | 845 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 1144 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5778 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2010 | 2033 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2005 | 610 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 985 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 283 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15911 | 0.010 |
Why?
|
| Cell Movement | 1 | 2010 | 2472 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 1419 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1341 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1260 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 654 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1233 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5697 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 365 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 4255 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 2004 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6398 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1273 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 1042 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7784 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8696 | 0.010 |
Why?
|
| Dependovirus | 1 | 1998 | 142 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 7383 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 938 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 5310 | 0.010 |
Why?
|
| Clemastine | 1 | 1995 | 1 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2178 | 0.010 |
Why?
|
| Metoclopramide | 1 | 1995 | 34 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 1525 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1998 | 1275 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 3118 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 1857 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 5759 | 0.010 |
Why?
|